ClinVar Miner

Submissions for variant NM_000051.3(ATM):c.2921+1G>C (rs587781558)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000217319 SCV000277701 likely pathogenic Hereditary cancer-predisposing syndrome 2017-06-21 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Well-characterized mutation at same position,Alterations at the canonical donor/acceptor sites (+/- 1, 2) without splicing assay data in support of pathogenicity,In silico models in agreement (deleterious) and/or completely conserved position in appropriate species,Alterations at the canonical donor/acceptor sites (+/- 1, 2) without other strong (b-level) evidence supporting pathogenicity
Color RCV000217319 SCV000682088 likely pathogenic Hereditary cancer-predisposing syndrome 2018-08-24 criteria provided, single submitter clinical testing
Counsyl RCV000167947 SCV000795509 likely pathogenic Ataxia-telangiectasia syndrome 2017-11-08 criteria provided, single submitter clinical testing
GeneDx RCV000236109 SCV000293826 pathogenic not provided 2016-11-21 criteria provided, single submitter clinical testing This variant is denoted ATM c.2921+1G>C or IVS19+1G>C and consists of a G>C nucleotide substitution at the +1 position of intron 19 of the ATM gene. This variant destroys a canonical splice donor site and is predicted to cause abnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNA decay or to an abnormal protein product. Although c.2921+1G>C has not, to our knowledge, been published in the literature, another nucleotide change at this position, c.2921+1G>A, has been reported in multiple cases of classical Ataxia-telangiectasia and resulted in complete loss of the adjacent exon (Gilad 1996, García-Pérez 2001, Mitui 2003). Based on the current evidence, we consider ATM c.2921+1G>C to be pathogenic.
Invitae RCV000167947 SCV000218595 pathogenic Ataxia-telangiectasia syndrome 2018-11-06 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 19 of the ATM gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with an ATM-related disease. ClinVar contains an entry for this variant (Variation ID: 188097). A different nucleotide change at this position, c.2921+1G>A, has been reported in individuals affected with ataxia-telangiectasia both in the homozygous state and as compound heterozygous with a second pathogenic ATM variant (PMID: 8845835, 11298136, 12815592, 23322442). The G>A sequence change has been reported to lead to aberrant splicing and exon skipping (PMID: 8845835). These data indicate that this nucleotide is crucial for normal RNA splicing. For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.